Plant derived bioactive compounds for the treatment of neurodegeneration and neuroimmune disorders associated with the complement system

Abstract

The complement system is a key component of the innate immune system that mediates the clearance of pathogens, apoptotic cells, and cellular debris. However, the complement system also has diverse roles in the central nervous system (CNS), where it regulates synaptic pruning, neural plasticity, and neuroinflammation. Dysregulation of the complement system has been implicated in various neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, epilepsy, stroke, and traumatic brain injury. In these conditions, excessive or chronic activation of the complement system may lead to synaptic loss, neuronal damage, immune dysregulation, and inflammation, which leads to exacerbating the disease’s progression and severity. Moreover, the complement system may interact with infectious agents that invade the CNS, such as bacteria, viruses, fungi, and parasites, and modulate their pathogenicity and host response. Therefore, understanding the complex interplay between the complement system and the CNS is crucial for developing novel therapeutic strategies to prevent or treat neurodegenerative and neuroimmune disorders. Natural compounds, such as plant extracts, phytochemicals, and nutraceuticals, have emerged as promising candidates for modulating the complement system and its effects on the CNS. These compounds may exert anti-inflammatory, antioxidant, neuroprotective, and immunomodulatory effects by regulating the expression of various complement components and pathways. In this review, we summarized the current knowledge on the roles of the complement system in human neurodegenerative disorders and the benefits of natural compounds for complement-targeted therapy.

Keywords

Complement systems / neurodegeneration / neuroimmune disorders / phytochemicals / therapeutic

References

[1] Ekdahl KN, Persson B, Mohlin C, Sandholm K, Skattum L, Nilsson B. Interpretation of Serological Complement Biomarkers in Disease. Front Immunol. 2018; 9: 2237.

[2] Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation. 2020; 17: 354.

[3] Willems E, Alkema W, Keizer-Garritsen J, Suppers A, Flier Mvd, Philipsen RHLA, et al. Biosynthetic homeostasis and resilience of the complement system in health and infectious disease. EBioMedicine. 2019; 45: 303-13.

[4] Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, Taylor SM. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta. 2006; 374: 33-45.

[5] Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol. 1999; 19: 173-98.

[6] Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med. 2011; 17: 317-29.

[7] Qu H, Ricklin D, Lambris JD. Recent developments in low molecular weight complement inhibitors. Mol Immunol. 2009; 47: 185-95.

[8] Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol. 2010; 28: 131-55.

[9] Wallis R. Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway. Immunobiology. 2007; 212: 289-99.

[10] Sørensen R, Thiel S, Jensenius JC. Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol. 2005; 27: 299-319.

[11] Nesargikar PN, Spiller B, Chavez R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol (Bp). 2012; 2: 103-11.

[12] Morgan BP, Gommerman JL, Ramaglia V. An “Outside-In” and “Inside-Out” Consideration of Complement in the Multiple Sclerosis Brain: Lessons From Development and Neurodegenerative Diseases. Front Cell Neurosci. 2021; 14: 600656.

[13] Kanmogne M, Klein RS. Neuroprotective versus Neuroinflammatory Roles of Complement: From Development to Disease. Trends Neurosci. 2021; 44: 97-109.

[14] Sotto AD, Vitalone A, Giacomo SD. Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview. Vaccines (Basel). 2020; 8: 468.

[15] Koul B, Farooq U, Yadav D, Song M. Phytochemicals: A Promising Alternative for the Prevention of Alzheimer’s Disease. Life (Basel). 2023; 13: 999.

[16] Limanaqi F, Biagioni F, Mastroiacovo F, Polzella M, Lazzeri G, Fornai F. Merging the Multi-Target Effects of Phytochemicals in Neurodegeneration: From Oxidative Stress to Protein Aggregation and Inflammation. Antioxidants (Basel). 2020; 9: 1022.

[17] Ricklin D, Lambris JD. Preformed mediators of defense-Gatekeepers enter the spotlight. Immunol Rev. 2016; 274: 5-8.

[18] Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011; 343: 227-35.

[19] Tan SM, Snelson M, Østergaard JA, Coughlan MT. The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease. Antioxid Redox Signal. 2022; 37: 781-801.

[20] Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007; 171: 715-27.

[21] Oksjoki R, Kovanen PT, Meri S, Pentikainen MO. Function and regulation of the complement system in cardiovascular diseases. Front Biosci. 2007; 12: 4696-708.

[22] Moreno-Navarrete JM, Fernández-Real JM. The complement system is dysfunctional in metabolic disease: Evidences in plasma and adipose tissue from obese and insulin resistant subjects. Semin Cell Dev Biol. 2019; 85: 164-72.

[23] Sina C, Kemper C, Derer S. The intestinal complement system in inflammatory bowel disease: Shaping intestinal barrier function. Semin Immunol. 2018; 37: 66-73.

[24] Pandya PH, Wilkes DS. Complement system in lung disease. Am J Respir Cell Mol Biol. 2014; 51: 467-73.

[25] Chen Y, Chu JMT, Chang RCC, Wong GTC. The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration. Biomolecules. 2022; 12: 337.

[26] Orsini F, Blasio DD, Zangari R, Zanier ER, Simoni MD. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci. 2014; 8: 380.

[27] Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007; 131: 1164-78.

[28] Fuchs A, Pinto AK, Schwaeble WJ, Diamond MS. The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology. 2011; 412: 101-9.

[29] Ziabska K, Ziemka-Nalecz M, Pawelec P, Sypecka J, Zalewska T. Aberrant Complement System Activation in Neurological Disorders. Int J Mol Sci. 2021; 22: 4675.

[30] Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012; 35: 369-89.

[31] Warwick CA, Keyes AL, Woodruff TM, Usachev YM. The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. J Biol Chem. 2021; 297: 101085.

[32] Boisvert MM, Erikson GA, Shokhirev MN, Allen NJ. The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. Cell Rep. 2018; 22: 269-85.

[33] You J, Youssef MMM, Santos JR, Lee J, Park J. Microglia and Astrocytes in Amyotrophic Lateral Sclerosis: Disease-Associated States, Pathological Roles, and Therapeutic Potential. Biology (Basel). 2023; 12: 1307.

[34] Kolev MV, Ruseva MM, Harris CL, Morgan BP, Donev RM. Implication of complement system and its regulators in Alzheimer’s disease. Curr Neuropharmacol. 2009; 7: 1-8.

[35] Gasque P, Morgan BP. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology. 1996; 89: 338-47.

[36] López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153: 1194-217.

[37] Lewis ED, Wu D, Meydani SN. Age-associated alterations in immune function and inflammation. Prog Neuropsychopharmacol Biol Psychiatry. 2022; 118: 110576.

[38] Zheng R, Zhang Y, Zhang K, Yuan Y, Jia S, Liu J. The Complement System, Aging, and Aging-Related Diseases. Int J Mol Sci. 2022; 23: 8689.

[39] Armento A, Ueffing M, Clark SJ. The complement system in age-related macular degeneration. Cell Mol Life Sci. 2021; 78: 4487-505.

[40] Petersen KS, Smith C. Ageing-Associated Oxidative Stress and Inflammation Are Alleviated by Products from Grapes. Oxid Med Cell Longev. 2016; 2016: 6236309.

[41] Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017; 12: 25-52.

[42] Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012; 26: 203-34.

[43] Sun S. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017; 17: 545-58.

[44] Luo S, Xu H, Gong X, Shen J, Chen X, Wu Z. The complement C3a-C3aR and C5a-C5aR pathways promote viability and inflammation of human retinal pigment epithelium cells by targeting NF-κB signaling. Exp Ther Med. 2022; 24: 493.

[45] Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ. 2013; 37: 284-91.

[46] Geller A, Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Front Immunol. 2019; 10: 1074.

[47] Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018; 14: 26-47.

[48] Fernando N, Wong JHC, Das S, Dietrich C, Aggio-Bruce R, Cioanca AV, et al. MicroRNA-223 Regulates Retinal Function and Inflammation in the Healthy and Degenerating Retina. Front Cell Dev Biol. 2020; 8: 516.

[49] Li TR, Jia YJ, Ma C, Qiu WY, Wang Q, Shao XQ, et al. The role of the microRNA-146a/complement factor H/interleukin-1β-mediated inflammatory loop circuit in the perpetuate inflammation of chronic temporal lobe epilepsy. Dis Model Mech. 2018; 11: dmm031708.

[50] Zingale VD, Gugliandolo A, Mazzon E. MiR-155: An Important Regulator of Neuroinflammation. Int J Mol Sci. 2021; 23: 90.

[51] Choi D, Kim J, Yang JW, Kim JH, Park S, Shin JI. Dysregulated MicroRNAs in the Pathogenesis of Systemic Lupus Erythematosus: A Comprehensive Review. Int J Biol Sci. 2023; 19: 2495-514.

[52] Choi YA, Jeong A, Woo CH, Cha SC, Park DY, Sagong M. Aqueous microRNA profiling in age-related macular degeneration and polypoidal choroidal vasculopathy by next-generation sequencing. Sci Rep. 2023; 13: 1274.

[53] Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016; 48: 134-43.

[54] Loeffler DA, Camp DM, Conant SB. Complement activation in the Parkinson’s disease substantia nigra: an immunocytochemical study. J Neuroinflammation. 2006; 3: 29.

[55] Chen Z, Zhong C. Oxidative stress in Alzheimer’s disease. Neurosci Bull. 2014; 30: 271-81.

[56] Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell. 2017; 169: 1276-90.e17.

[57] Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A, et al. Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner. Nat Commun. 2017; 8: 717.

[58] Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer’s disease and other neurodegenerative disorders. Nat Rev Neurol. 2018; 14: 133-50.

[59] Lee H, Pienaar IS. Disruption of the blood-brain barrier in Parkinson’s disease: curse or route to a cure? Front Biosci (Landmark Ed). 2014; 19: 272-80.

[60] Block ML, Calderón-Garcidueñas L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends Neurosci. 2009; 32: 506-16.

[61] Calderón-Garcidueñas L, Mora-Tiscareño A. Air pollution, neuroinflammation and neurodegeneration: What neurotoxicology tells us about neurodegenerative diseases. In Handbook of Clinical Neurology. Amsterdam: Elsevier; 2019. pp. 293-323.

[62] Alexaki VI. The Impact of Obesity on Microglial Function: Immune, Metabolic and Endocrine Perspectives. Cells. 2021; 10: 1584.

[63] Maldonado-Ruiz R, Montalvo-Martínez L, Fuentes-Mera L, Camacho A. Microglia activation due to obesity programs metabolic failure leading to type two diabetes. Nutr Diabetes. 2017; 7: e254.

[64] Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017; 7: 13537.

[65] Sochocka M, Donskow-Łysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer’s Disease-a Critical Review. Mol Neurobiol. 2019; 56: 1841-51.

[66] Gasparoni G, Bultmann S, Lutsik P, Kraus TFJ, Sordon S, Vlcek J, et al. DNA methylation analysis on purified neurons and glia dissects age and Alzheimer’s disease-specific changes in the human cortex. Epigenetics Chromatin. 2018; 11: 41.

[67] Kim TW, Lee S, Oh BM, Lee H, Uhm TG, Min J, et al. Epigenetic modification of TLR4 promotes activation of NF-κB by regulating methyl-CpG-binding domain protein 2 and Sp1 in gastric cancer. Oncotarget. 2016; 7: 4195-209.

[68] Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014; 32: 433-59.

[69] Józsi M, Tortajada A, Uzonyi B, Jorge EGd, Córdoba SRd. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. 2015; 36: 374-84.

[70] Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol. 2015; 6: 262.

[71] Kaartinen K, Martola L, Meri S. Atypical hemolytic-uremic syndrome. Duodecim. 2017; 133: 539-47.

[72] Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011; 7: e1002079.

[73] Baidya F, Bohra M, Datta A, Sarmah D, Shah B, Jagtap P, et al. Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. Immunology. 2021; 162: 160-78.

[74] Magdalon J, Mansur F, Silva ALTE, Goes VAd, Reiner O, Sertié AL. Complement System in Brain Architecture and Neurodevelopmental Disorders. Front Neurosci. 2020; 14: 23.

[75] Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020; 16: 601-17.

[76] Tenner AJ, Stevens B, Woodruff TM. New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. Mol Immunol. 2018; 102: 3-13.

[77] Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, et al. Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neurosci Lett. 2001; 305: 165-8.

[78] Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Localization and cell association of C1q in Alzheimer’s disease brain. Exp Neurol. 1996; 138: 22-32.

[79] Presumey J, Bialas AR, Carroll MC. Complement System in Neural Synapse Elimination in Development and Disease. Adv Immunol. 2017; 135: 53-79.

[80] Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016; 352: 712-16.

[81] Zelek WM, Bevan RJ, Nimmo J, Dewilde M, Strooper BD, Morgan BP. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer’s disease mouse model. Brain. 2024;awae278.

[82] Fonseca MI, Ager RR, Chu S, Yazan O, Sanderson SD, LaFerla FM, et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer’s disease. J Immunol. 2009; 183: 1375-83.

[83] Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol. 2011; 48: 1592-603.

[84] Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022; 22: 657-73.

[85] Chi X, Yin S, Sun Y, Kou L, Zou W, Wang Y, et al. Astrocyte-neuron communication through the complement C3-C3aR pathway in Parkinson’s disease. Brain Behav Immun. 2024; 123: 229-43.

[86] Liang Y, Li S, Guo Q, Zhang Y, Wen C, Zou Q, et al. Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. Brain Res. 2007; 1178: 132-40.

[87] Depboylu C, Schorlemmer K, Klietz M, Oertel WH, Weihe E, Höglinger GU, et al. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease. J Neuroimmunol. 2011; 236: 39-46.

[88] Hou L, Wang K, Zhang C, Sun F, Che Y, Zhao X, et al. Complement receptor 3 mediates NADPH oxidase activation and dopaminergic neurodegeneration through a Src-Erk-dependent pathway. Redox Biol. 2018; 14: 250-60.

[89] Chen M, Hu Z, Ding J, Du R, Hu G. Astrocytic Kir6.1 deletion aggravates neurodegeneration in the lipopolysaccharide-induced mouse model of Parkinson’s disease via astrocyte-neuron cross talk through complement C3-C3R signaling. Brain Behav Immun. 2021; 95: 310-20.

[90] Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington’s disease. Exp Neurol. 1999; 159: 362-76.

[91] Wilton DK, Mastro K, Heller MD, Gergits FW, Willing CR, Fahey JB, et al. Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington’s disease. Nat Med. 2023; 29: 2866-84.

[92] Crotti A, Glass CK. The choreography of neuroinflammation in Huntington’s disease. Trends Immunol. 2015; 36: 364-73.

[93] Fatoba O, Ohtake Y, Itokazu T, Yamashita T. Immunotherapies in Huntington’s disease and α-Synucleinopathies. Front Immunol. 2020; 11: 337.

[94] Larkin PB, Muchowski PJ. Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington’s Disease. J Huntingtons Dis. 2012; 1: 107-18.

[95] Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med. 2018; 378: 840-51.

[96] Körtvelyessy P, Bauer J, Stoppel CM, Brück W, Gerth I, Vielhaber S, et al. Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015; 2: e75.

[97] Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018; 83: 166-77.

[98] Liu J, Lin F, Strainic MG, An F, Miller RH, Altuntas CZ, et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol. 2008; 180: 5882-9.

[99] Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012; 135: 1622-38.

[100] Smets I, Titulaer MJ. Antibody Therapies in Autoimmune Encephalitis. Neurotherapeutics. 2022; 19: 823-31.

[101] Michailidou I, Jongejan A, Vreijling JP, Georgakopoulou T, Wissel MBd, Wolterman RA, et al. Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathol Commun. 2018; 6: 36.

[102] Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo. Mol Immunol. 2008; 45: 395-405.

[103] Saez-Calveras N, Stuve O. The role of the complement system in Multiple Sclerosis: A review. Front Immunol. 2022; 13: 970486.

[104] Manouchehri N, Salinas VH, Yeganeh NR, Pitt D, Hussain RZ, Stuve O. Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Front Neurol. 2022; 13: 854390.

[105] Papadopoulos D, Magliozzi R, Mitsikostas DD, Gorgoulis VG, Nicholas RS. Aging, Cellular Senescence, and Progressive Multiple Sclerosis. Front Cell Neurosci. 2020; 14: 178.

[106] Lloyd AF, Miron VE. The pro-remyelination properties of microglia in the central nervous system. Nat Rev Neurol. 2019; 15: 447-58.

[107] Niculescu T, Weerth S, Niculescu F, Cudrici C, Rus V, Raine CS, et al. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J Immunol. 2004; 172: 5702-6.

[108] Traugott U, Scheinberg LC, Raine CS. On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation. J Neuroimmunol. 1985; 8: 1-14.

[109] Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47: 707-17.

[110] Lucchinetti C, Brück W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol. 2001; 14: 259-69.

[111] Michailidou I, Naessens DMP, Hametner S, Guldenaar W, Kooi E, Geurts JJG, et al. Complement C3 on microglial clusters in multiple sclerosis occur in chronic but not acute disease: Implication for disease pathogenesis. Glia. 2017; 65: 264-77.

[112] Liddelow SA, Barres BA. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity. 2017; 46: 957-67.

[113] Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017; 541: 481-7.

[114] Kirby L, Castelo-Branco G. Crossing boundaries: Interplay between the immune system and oligodendrocyte lineage cells. Semin Cell Dev Biol. 2021; 116: 45-52.

[115] Ingram G, Loveless S, Howell OW, Hakobyan S, Dancey B, Harris CL, et al. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun. 2014; 2: 53.

[116] Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci. 1999; 22: 397-402.

[117] Shibata M, Makioka K, Nakamura T, Kasahara H, Yamazaki T, Takatama M, et al. Role of complement activation and disruption of the blood-brain barrier in the pathogenesis of multiple system atrophy. Neurosci Lett. 2024; 822: 137642.

[118] Jacob A, Hack B, Chen P, Quigg RJ, Alexander JJ. C5a/CD88 signaling alters blood-brain barrier integrity in lupus through NFκB. J Neurochem. 2011; 119: 1041-51.

[119] Oechtering J, Stein K, Schaedelin SA, Maceski AM, Orleth A, Meier S, et al. Complement Activation Is Associated With Disease Severity in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024; 11: e200212.

[120] Dalakas MC, Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011; 7: 507-17.

[121] Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014; 82: 879-86.

[122] Fridkis-Hareli M, Strominger JL. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol. 1998; 160: 4386-97.

[123] Almas T, Niaz MA, Sattar Y, Khedro T, Kanawati A, Yazji K, et al. Chronic inflammatory demyelinating polyneuropathy as a paraneoplastic manifestation of colorectal carcinoma: What do we know? Ann Med Surg (Lond). 2021; 68: 102545.

[124] Querol LA, Hartung H, Lewis RA, Doorn PAv, Hammond TR, Atassi N, et al. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics. 2022; 19: 864-73.

[125] Quast I, Keller CW, Hiepe F, Tackenberg B, Lünemann JD. Terminal complement activation is increased and associated with disease severity in CIDP. Ann Clin Transl Neurol. 2016; 3: 730-5.

[126] Mathey EK, Park SB, Hughes RAC, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015; 86: 973-85.

[127] Dimachkie MM, Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol. 2013; 15: 350-66.

[128] Zelek WM, Morgan BP. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends Pharmacol Sci. 2022; 43: 615-28.

[129] Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev. 2021; 73: 792-827.

[130] Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007; 25: 1265-75.

[131] Thurman JM, Quintrec ML. Targeting the complement cascade: novel treatments coming down the pike. Kidney Int. 2016; 90: 746-52.

[132] Carpanini SM, Torvell M, Morgan BP. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System. Front Immunol. 2019; 10: 362.

[133] Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Mol Oral Microbiol. 2016; 31: 3-17.

[134] Gavriilaki M, Kimiskidis VK, Gavriilaki E. Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Pharmaceuticals (Basel). 2020; 13: 341.

[135] Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends Immunol. 2017; 38: 383-94.

[136] Reis ES, DeAngelis RA, Chen H, Resuello RRG, Ricklin D, Lambris JD. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology. 2015; 220: 476-82.

[137] Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019; 18: 707-29.

[138] Schmidt CQ, Schrezenmeier H, Kavanagh D. Complement and the prothrombotic state. Blood. 2022; 139: 1954-72.

[139] Fan Y, Wang Y, Yu S, Chang J, Yan Y, Wang Y, et al. Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review. Chin Med. 2021; 16: 67.

[140] Kulkarni AP, Ghebremariam YT, Kotwal GJ. Curcumin inhibits the classical and the alternate pathways of complement activation. Ann N Y Acad Sci. 2005; 1056: 100-12.

[141] Cuzzola VF, Ciurleo R, Giacoppo S, Marino S, Bramanti P. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries. CNS Neurol Disord Drug Targets. 2011; 10: 849-62.

[142] Sahu A, Rawal N, Pangburn MK. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem Pharmacol. 1999; 57: 1439-46.

[143] Kulkarni AP, Kellaway LA, Kotwal GJ. Herbal complement inhibitors in the treatment of neuroinflammation: future strategy for neuroprotection. Ann N Y Acad Sci. 2005; 1056: 413-29.

[144] Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015; 14: 857-77.

[145] Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ. Flavonoids as Potential Anti-Inflammatory Molecules: A Review. Molecules. 2022; 27: 2901.

[146] Apers S, Huang Y, Miert SV, Dommisse R, Berghe DV, Pieters L, et al. Characterisation of new oligoglycosidic compounds in two Chinese medicinal herbs. Phytochem Anal. 2002; 13: 202-6.

[147] Park SH, Oh SR, Jung KY, Lee IS, Ahn KS, Kim JH, et al. Acylated flavonol glycosides with anti-complement activity from Persicaria lapathifolia. Chem Pharm Bull (Tokyo). 1999; 47: 1484-6.

[148] al-Sereiti MR, Abu-Amer KM, Sen P. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J Exp Biol. 1999; 37: 124-30.

[149] Peake PW, Pussell BA, Martyn P, Timmermans V, Charlesworth JA. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase. Int J Immunopharmacol. 1991; 13: 853-7.

[150] Thomet OA, Wiesmann UN, Schapowal A, Bizer C, Simon HU. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus . Biochem Pharmacol. 2001; 61: 1041-7.

[151] Kosasi S, Hart LA, Dijk Hv, Labadie RP. Inhibitory activity of Jatropha multifida latex on classical complement pathway activity in human serum mediated by a calcium-binding proanthocyanidin . J Ethnopharmacol. 1989; 27: 81-9.

[152] Hart LAt, Berg AJvd, Kuis L, Dijk Hv, Labadie RP. An anti-complementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of Aloe vera . Planta Med. 1989; 55: 509-12.

[153] Hart LAt, Enckevort PHv, Dijk Hv, Zaat R, Silva KTd, Labadie RP. Two functionally and chemically distinct immunomodulatory compounds in the gel of Aloe vera . J Ethnopharmacol. 1988; 23: 61-71.

[154] Berg AJvd, Horsten SF, Bosch JJKd, Kroes BH, Beukelman CJ, Leeflang BR, et al. Curcacycline A-a novel cyclic octapeptide isolated from the latex of Jatropha curcas L . FEBS Lett. 1995; 358: 215-8.

[155] Shahat AA, Cos P, Hermans N, Apers S, Bruyne TD, Pieters L, et al. Anticomplement and antioxidant activities of new acetylated flavonoid glycosides from Centaurium spicatum . Planta Med. 2003; 69: 1153-6.

[156] Chiou W, Peng C, Chen C, Chou C. Anti-inflammatory properties of piperlactam S: modulation of complement 5a-induced chemotaxis and inflammatory cytokines production in macrophages. Planta Med. 2003; 69: 9-14.

[157] Zhao JF, Kiyohara H, Matsumoto T, Yamada H. Anti-complementary acidic polysaccharides from roots of Lithospermum euchromum . Phytochemistry. 1993; 34: 719-24.

[158] Pieroni A, Heimler D, Pieters L, Poel Bv, Vlietinck AJ. In vitro anti-complementary activity of flavonoids from olive (Olea europaea L.) leaves . Pharmazie. 1996; 51: 765-8.

[159] Thabrew MI, Silva KTd, Labadie RP, Bie PAd, Berg Bvd. Immunomodulatory activity of three Sri-Lankan medicinal plants used in hepatic disorders. J Ethnopharmacol. 1991; 33: 63-6.

[160] Blondin C, Chaubet F, Nardella A, Sinquin C, Jozefonvicz J. Relationships between chemical characteristics and anticomplementary activity of fucans. Biomaterials. 1996; 17: 597-603.

[161] Benencia F, Courrèges MC, Coulombié FC. Anti-inflammatory activities of Trichilia glabra aqueous leaf extract . J Ethnopharmacol. 2000; 71: 293-300.

[162] Ivanovska ND, Dimov VB, Pavlova S, Bankova VS, Popov SS. Immunomodulatory action of propolis. V. Anticomplementary activity of a water-soluble derivative. J Ethnopharmacol. 1995; 47: 135-43.

[163] Ou Y, Jiang Y, Li H, Zhang Y, Lu Y, Chen D. Polysaccharides from Arnebia euchroma Ameliorated Endotoxic Fever and Acute Lung Injury in Rats Through Inhibiting Complement System . Inflammation. 2017; 40: 275-84.

[164] Xie J, Di H, Li H, Cheng X, Zhang Y, Chen D. Bupleurum chinense DC polysaccharides attenuates lipopolysaccharide-induced acute lung injury in mice . Phytomedicine. 2012; 19: 130-7.

[165] Xu Y, Zhang Y, Ou Y, Lu X, Pan L, Li H, et al. Houttuyniacordata Thunb. polysaccharides ameliorates lipopolysaccharide-induced acute lung injury in mice . J Ethnopharmacol. 2015; 173: 81-90.

[166] Xia L, Deji, Zhu M, Chen D, Lu Y. Juniperus pingii var. wilsonii acidic polysaccharide: Extraction, characterization and anticomplement activity . Carbohydr Polym. 2020; 231: 115728.

[167] Zhi H, Zhu H, Zhang Y, Lu Y, Li H, Chen D. In vivo effect of quantified flavonoids-enriched extract of Scutellaria baicalensis root on acute lung injury induced by influenza A virus . Phytomedicine. 2019; 57: 105-16.

[168] Lee Y, Lin M, Cheng C, Chang L, Liu T, Hung S. Inhibitory effects of areca nut extract on expression of complement receptors and fc receptors in human neutrophils. J Periodontol. 2014; 85: 1096-106.

[169] Jacob A, Chaves L, Eadon MT, Chang A, Quigg RJ, Alexander JJ. Curcumin alleviates immune-complex-mediated glomerulonephritis in factor-H-deficient mice. Immunology. 2013; 139: 328-37.

[170] Ge X, Du Y, Chen J, Zhu N, Yao J, Zhang X, et al. Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis. Front Oncol. 2021; 11: 751904.

[171] Knaus U, Wagner H. Effects of boswellic acid of Boswellia serrata and other triterpenic acids on the complement system . Phytomedicine. 1996; 3: 77-80.

[172] Pérez-Rosés R, Risco E, Vila R, Peñalver P, Cañigueral S. Effect of some essential oils on phagocytosis and complement system activity. J Agric Food Chem. 2015; 63: 1496-504.

[173] Vieira SF, Reis RL, Ferreira H, Neves NM. Plant-derived bioactive compounds as key players in the modulation of immune-related conditions. Phytochem Rev. 2024: 1-118.

[174] Juan TS, Wilson DR, Wilde MD, Darlington GJ. Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3. Proc Natl Acad Sci U S A. 1993; 90: 2584-8.

[175] Schaefer M, Konrad S, Thalmann J, Rheinheimer C, Johswich K, Sohns B, et al. The transcription factors AP-1 and Ets are regulators of C3a receptor expression. J Biol Chem. 2005; 280: 42113-23.

[176] Maranto J, Rappaport J, Datta PK. Regulation of complement component C3 in astrocytes by IL-1beta and morphine. J Neuroimmune Pharmacol. 2008; 3: 43-51.

[177] Yang J, Ahn H, Chang M, Narasimhan P, Chan PH, Song YS. Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J Neurochem. 2013; 124: 523-35.